

# What Trump's FTC Picks Mean for Bio-Pharma Dealmaking and PBMs

MEDIA MENTIONS | LESS THAN 1 MIN READ

December 16, 2024

By: Jared Whitlock


Endpoints News

Axinn managing partner Jeny Maier was quoted in the *Endpoint News* article, "What Trump's FTC Picks Mean for Bio-Pharma Dealmaking and PBMs."

Click [here](#) to access the publication. A subscription is required.

## Related People

---



Jeny M. Maier

# Related Services

---

Antitrust

To subscribe to our publications, [click here](#).

## Featured Insights

- GCR Live: Law Leaders Europe 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Annual Meeting 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR    ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- Hartford HealthCare Black and Red Gala 2025  
**SPONSORSHIP    ANTITRUST**
- Informa CompLaw Antitrust West Coast Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Health Care Transactions Program 2025  
**SPONSORSHIP    ANTITRUST**
- IAM Live: Auto IP USA 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**

- ACI 21st Annual Paragraph IV Conference

**SPEAKING ENGAGEMENT      INTELLECTUAL PROPERTY**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved